Health Condition 1: B342- Coronavirus infection, unspecified
Conditions
Interventions
Intervention1: SSV Formulation Tablets: Each tablet of 500 mg to be consumed orally twice a day immediately after meals for 15 days.
Control Intervention1: Not Applicable: Not Applicable
Sponsors
SSV Phytopharmaceuticals
Eligibility
Inclusion criteria
Inclusion criteria: 1. Recent history of contact with COVID-19 positive people and are advised to be quarantined or has symptoms which include cough, fever with or without chills and difficulty in breathing. 2. Willing to provide informed consent.
Exclusion criteria
Exclusion criteria: 1. Presence of acute hypoxic respiratory failure. 2. Intensive care unit (ICU) stay. 3. Patients who need mechanical ventilation. 4. Category 6 or 5 based on modified 7-category ordinal scale of clinical status.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in ambulatory patients who are assessed daily for symptoms which include cough, fever with or without chills and difficulty in breathing for the period they are in quarantine. Timepoint: Baseline, telephonically everyday and day 15. | — |
Secondary
| Measure | Time frame |
|---|---|
| The ambulatory patients who did not require artificial ventilation or were not admitted to ICU during the period of quarantine. Improvement in the clinical variables including Pro inflammatory cytokine IL-6 from baseline to end of the quarantine period i.e. 15 days.Timepoint: Baseline, telephonically everyday and day 15. Clinical variables including Pro inflammatory cytokine IL-6 will be recorded at baseline and at day 15. | — |
Countries
India
Contacts
Public ContactDr Samadhan Patil
Shreepad Shree Vallabh SSV Phytopharmaceuticals
Outcome results
None listed